Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)
Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors
Sponsor: Bristol-Myers Squibb
Listed as NCT03865082, this PHASE2 trial focuses on Solid Tumor and remains ongoing. Sponsored by Bristol-Myers Squibb, it has been updated 13 times since 2019, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Mar 2022 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2021 — Mar 2022 [monthly]
Recruiting PHASE2
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE2
▶ Show 8 earlier versions
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Nov 2020 — Dec 2020 [monthly]
Recruiting PHASE2
-
Dec 2019 — Nov 2020 [monthly]
Recruiting PHASE2
-
Nov 2019 — Dec 2019 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2019 — Nov 2019 [monthly]
Not Yet Recruiting PHASE2
-
Jun 2019 — Sep 2019 [monthly]
Not Yet Recruiting PHASE2
-
May 2019 — Jun 2019 [monthly]
Not Yet Recruiting PHASE2
-
Apr 2019 — May 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Bristol-Myers Squibb
- Idera Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .